MOMENTA PHARMA (NASDAQ:MNTA)
11.05
0.24 (2.13%)
| MOMENTA PHARMA (NASDAQ:MNTA) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $11.29 | 52 Week High | $12.56 | ||
| Open | $11.25 | 52 Week Low | $6.47 | ||
| Day High | $11.60 | P/E | N/A | ||
| Day Low | $11.00 | EPS | $-1.77 | ||
| Volume | 622,710 | ||||
| More MNTA Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| ABMD | 1 | AWH | 1 |
| COHR | 1 | EURX | 1 |
| HAFC | 1 | IRF | 1 |
| LXP | 1 | NHWK | 1 |
| PPCO | 1 | SD | 1 |
| TECUA | 1 | VTIV | 1 |
Entities who have mentioned MNTA
- 13G | View Related Stories »
- Deutsche Bank | View Related Stories »
- Citi | View Related Stories »
- Canaccord Adams | View Related Stories »
- UBS | View Related Stories »
- Notable Analyst Rating Changes | View Related Stories »
- Banc of America | View Related Stories »
- RBC Capital | View Related Stories »
- Bear Stearns | View Related Stories »
- Morgan Joseph | View Related Stories »
- Morgan Stanley | View Related Stories »
- Sanford C. Bernstein | View Related Stories »
- Merriman Curhan Ford | View Related Stories »
- Wedbush Morgan | View Related Stories »
- After-Hours Movers | View Related Stories »
- Carl Icahn | View Related Stories »
- Initial Jobless Claims | View Related Stories »
- GLG Partners | View Related Stories »
- Trading Radar | View Related Stories »
- Life, Style and Real Estate | View Related Stories »
- Lazard | View Related Stories »
- Bain Capital | View Related Stories »
- JPMorgan | View Related Stories »
- Goldman Sachs | View Related Stories »
- Wachovia | View Related Stories »
View All Major News StreetInsider.com Major News for MNTA
- Momenta Pharma (MNTA) Posts Q3 Loss of $0.38, Tops by 2c
- Momenta Pharmaceuticals (MNTA) Tops Q3 EPS by 2c; Revs Light
- Momenta Pharma (MNTA) Reports Q4 Loss of $0.50
View All ReportsStreetInsider.com Reports on MNTA
- Momenta Pharmaceuticals (MNTA) Dec volatility at 89, March at 121 into FDA
- Oppenheimer Upgrades Momenta Pharmaceuticals (MNTA) to Outperform
- Notable Analyst Rating Changes 11/18: SII, ZMH, FSLR, PHM Upgraded; TGT, ADSK, VIP, JEC, PARD Downgraded
- Canaccord Adams Initiates Coverage on Momenta Pharmaceuticals (MNTA) with a Buy
- Momenta Pharmaceuticals (MNTA) March put volatility elevated at 131
View All Press ReleasesCompany Press Releases on MNTA
- Momenta Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- Momenta Pharmaceuticals Reports Financial Results for the Third Quarter of 2009
- Momenta Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference
- Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Third Quarter 2009 Financial Results
- Momenta Pharmaceuticals, Inc. Announces Closing of Offering and Exercise of Over-Allotment Option
StreetInsider Reports on MNTA by Category
View All BlogsBlogs on MNTA
- Analyst upgrades, downgrades and initiations: CVS, FICO, HOTT, INTC, MNTA, TXN ...
- Momenta Pharmaceuticals, Inc. Q3 2009 Earnings Call Transcript
- Momenta Pharma's M-Enoxaparin: Timing Uncertain, Approval Likely
- Biotech News Bytes: Genzyme, ImmunoCellular, Momenta, Novo Nordisk
- BioMed News Bytes: Arena, Momenta, Vivus
View All FilingsSEC Filings on MNTA
- Form 4 MOMENTA PHARMACEUTICALS For: Nov 19 Filed by: Leicher Bruce
- Form 4 MOMENTA PHARMACEUTICALS For: Nov 16 Filed by: Shea Richard P
- Form SC 13G/A MOMENTA PHARMACEUTICALS Filed by: PRICE T ROWE ASSOCIATES INC /MD/
- Form 10-Q MOMENTA PHARMACEUTICALS For: Sep 30
- Form SC 13G/A MOMENTA PHARMACEUTICALS Filed by: FEDERATED INVESTORS INC /PA/
Comments on MNTA
No comments are currently available.
